Safety Study of Nebivolol for COPD Patients

The University of Chicago

Status and phase: Withdrawn; Phase 3; Phase 2

Conditions: High Blood Pressure

Treatments: Drug: Nebivolol; Drug: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01939990

11-0720

Details and patient eligibility

About

The purpose of this study is to demonstrate the safety and effectiveness of the study drug Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary Disease (COPD).

Full description

The study would be a randomized, placebo-controlled trial of 60 hypertensive patients with documented COPD greater than age 40.

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of high blood pressure and chronic obstructive pulmonary disease (COPD)

Exclusion criteria

• Asthma; Heart failur;
• End stage kidney disease;
• acute myocardial infarction,unstable angina, stroke or TIA within the past year;
• Females who are pregnant, lactating or women of childbearing potential who are not using approved method of contraception.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups, including a placebo group

Nebivolol

Active Comparator group

Description:

Group A will be given Nebivolol 5 to 10mg per day

Treatment:

Drug: Nebivolol

Placebo

Placebo Comparator group

Description:

Group B will be given Placebo.

Treatment:

Drug: Placebo